Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9

article OA: closed CC0 ⤵ 41 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
AI-generated summary by claude@2026-06, 2026-06-08

Metformin treatment in rats led to regression of endometriotic implants by modulating key molecules involved in oxidative stress, angiogenesis, and extracellular matrix remodeling.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Endometriosis Endometriosis Matrix Metalloproteinase 9 Metformin Superoxide Dismutase Tissue Inhibitor of Metalloproteinase-2 Vascular Endothelial Growth Factor A Animals Disease Models, Animal Endometriosis Endometriosis Endometrium Endometrium Endometrium Endometrium Female Hypoglycemic Agents Hypoglycemic Agents Immunohistochemistry Laparotomy

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (46)

Cited by (41)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:53.633898+00:00
License: CC0 · commercial use OK